New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:43 EDTAERIAerie Pharmaceuticals price target raised to $36 from $27 at RBC Capital
RBC Capital believes that Phase IIb results for Aerie's glaucoma treatment, Roclatan, lower the risks faced by the company. The firm says that the data would be good enough to support approval of the drug if the trial was a Phase III study. It keeps an Outperform rating on the shares.
News For AERI From The Last 14 Days
Check below for free stories on AERI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
07:33 EDTAERIAerie receives NOL for Rhopressa Phase 3 registration trial
Aerie Pharmaceuticals announced that it has received a No Objection Letter from Health Canada to conduct a Phase 3 registration trial of Rhopressa. The study, named “Rocket 3,” is designed to evaluate safety and tolerability of Rhopressa in patients over 12 months and is part of a broad Phase 3 program being conducted by Aerie. The company recently announced the commencement of two Phase 3 trials in the U.S., “Rocket 1” and “Rocket 2,” which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa. The company said, " Pending progress of the program and regulatory approvals, Aerie intends to commercialize Rhopressa in North American markets with its own sales force and will seek commercialization partners in other key territories, including Europe and Japan. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030."
July 14, 2014
07:37 EDTAERIAerie initiates Rhopressa Phase 3 registration trials
Subscribe for More Information
06:44 EDTAERIAerie Pharmaceuticals initiates Phase 3 trials of Rhopressa
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use